DV
Dividend Vision

KARD — Kardigan, Inc. Common Stock

Kardigan, Inc. Common Stock (KARD)

Total return is -8.2% over the past 0.2 years, 12.2 points behind SPY at 4.0%.

Kardigan, Inc. is a biopharmaceutical company developing medicines for cardiovascular diseases, particularly cardiomyopathies and heart failure, using a proprietary platform that combines AI-based tools, real-world clinical data, and cardiac-specific analytics alongside the Prolaio cardiovascular data collection platform. The company does not currently distribute dividends. Kardigan's focus on specialized cardiovascular therapeutics and clinical intelligence appeals to investors seeking exposure to targeted biotech development rather than near-term income.

KARD key facts

Asset type
Stock
Asset class
Equity
Inception date
06/18/2026
Last close
$20.20
Market cap
$1,887,735,552
Average volume
144700.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.58